Last reviewed · How we verify
powder BoNT-A (BOTOX/Vistabel)
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Moderate to severe glabellar lines (frown lines) in adults, Moderate to severe lateral canthal lines (crow's feet) in adults, Forehead lines in adults.
At a glance
| Generic name | powder BoNT-A (BOTOX/Vistabel) |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Neurotoxin; botulinum toxin type A |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Biologic |
| Therapeutic area | Dermatology; Neurology; Aesthetics |
| Phase | FDA-approved |
Mechanism of action
BoNT-A is a neurotoxin that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release at the presynaptic terminal. This prevents neuromuscular transmission, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.
Approved indications
- Moderate to severe glabellar lines (frown lines) in adults
- Moderate to severe lateral canthal lines (crow's feet) in adults
- Forehead lines in adults
- Cervical dystonia
- Chronic migraine
- Hyperhidrosis (excessive sweating)
- Spasticity
Common side effects
- Headache
- Injection site pain or bruising
- Eyelid ptosis
- Brow ptosis
- Facial asymmetry
- Muscle weakness
Key clinical trials
- Study Comparing Treatment With Alluzience vs Reconstituted Toxin (PHASE4)
- NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- powder BoNT-A (BOTOX/Vistabel) CI brief — competitive landscape report
- powder BoNT-A (BOTOX/Vistabel) updates RSS · CI watch RSS
- Galderma R&D portfolio CI